Pathogenesis of Type 1 Diabetes

Slide 1 · Pathogenesis of Type 1 Diabetes

Genetic susceptibility · Environmental hypotheses · Islet autoimmunity · β-cell failure

From loss of immune tolerance to insulin deficiency

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain type 1 diabetes through genetic risk, immune dysregulation and the natural history of β-cell failure.

Distinguish susceptibility from disease-defining autoimmune injury.

Relate HLA and immune-regulator loci to failures of self-tolerance.

Explain candidate environmental mechanisms without implying proof.

Connect islet-directed immune responses to presymptomatic stages and clinical onset.

Slide 3 · Type 1 diabetes is an autoimmune β-cell disease

The causal lesion is immune-mediated loss of pancreatic insulin-producing β cells.

Islet-specific autoimmunity

β-cell injury and loss

Insulin deficiency

Metabolic disease

Endogenous β-cell antigens become targets of autoreactive immune effector cells.

Progressive loss of functional β-cell reserve eventually produces insulin deficiency.

Metabolic disease follows the destructive immune process.

Slide 4 · The β cell is the principal injured endocrine cell

Define the precise cell target before considering disease risk.

Pancreatic islets contain insulin-producing β cells.

T1D preferentially destroys β cells through islet-directed autoimmunity.

The major functional consequence is inadequate endogenous insulin production.

Interpretive point

Disease mechanism: Target-cell loss, not merely a defect in receptor signaling.

Slide 5 · Insulin normally coordinates anabolic metabolism

T1D consequences are best understood against the normal actions of insulin.

Striated muscle

Muscle: Increases glucose uptake, glycogen formation and protein synthesis.

Adipose tissue

Adipose tissue: Supports lipid storage and restrains lipolysis.

Liver

Liver: Suppresses glucose synthesis while favoring glycogen synthesis.

Slide 6 · Loss of insulin disrupts several metabolic pathways

A single endocrine-cell lesion produces multisystem metabolic consequences.

β-cell loss

Less insulin

Disordered nutrient flux

Hyperglycemia / ketosis risk

Reduced insulin action impairs glucose utilization in major target tissues.

Failure to restrain hepatic glucose output aggravates hyperglycemia.

Loss of anti-lipolytic effects promotes mobilization of stored fat.

Slide 7 · T1D has an immune cause and a metabolic phenotype

Separate upstream pathogenic events from downstream clinical expression.

Immune pathogenesis

Autoreactivity

β-cell injury

Insulin reserve declines

Metabolic expression

Dysglycemia

Symptoms

Potential ketoacidosis

Upstream: Breakdown of tolerance to islet antigens and effector-cell activation.

Downstream: Insulin deficiency, dysglycemia and potential ketoacidosis.

Glucose elevation indicates functional failure but does not identify its cause.

Slide 8 · Clinical onset may conceal years of pathogenesis

A long silent interval can separate initiation of autoimmunity from symptomatic diabetes.

Autoimmunity

Silent reserve loss

Dysglycemia

Symptomatic T1D

Autoimmune activity may already be detectable before hyperglycemia.

β-cell loss gradually reduces compensatory insulin reserves.

Symptoms can emerge relatively abruptly once residual capacity is inadequate.

Slide 9 · Age at presentation does not define T1D

Historical age-based nomenclature fails to describe the full disease spectrum.

Older shorthand

“Juvenile-onset”

Age assumed to define cause

Mechanism-based label

Type 1 diabetes

Autoimmune β-cell destruction

T1D often begins in childhood and becomes manifest around puberty.

Onset also occurs in adulthood, including later adulthood.

“Juvenile-onset diabetes” is therefore not an appropriate disease label.

Slide 10 · Insulin requirement is not a unique classifier

The former label “insulin-dependent diabetes mellitus” is no longer preferred.

Many forms of diabetes eventually require insulin treatment.

In T1D, severe insulin deficiency makes replacement essential for survival in most patients.

Classification should follow pathophysiology, not treatment alone.

Interpretive point

Treatment requirement and etiologic classification answer different questions.

Slide 11 · Slowly progressive adult autoimmune diabetes

LADA illustrates heterogeneity in the tempo of autoimmune β-cell failure.

Typical abrupt recognition

Symptoms accompany marked loss

Of insulin reserve

LADA pattern

Slower progression

Insulin need may develop later

Latent autoimmune diabetes in adults (LADA) occurs in adulthood.

One or more diabetes-related autoantibodies distinguish it from typical antibody-negative T2D.

Insulin may not be needed at presentation but is eventually required in most patients.

Slide 12 · Three interacting determinants frame T1D pathogenesis

Genetics, environmental influences and immune effector responses are linked but not equivalent.

Genetic predisposition

Inherited variants set the susceptibility background.

Environmental influences

Environmental contributors remain incompletely established.

Failure of self-tolerance

A breach in islet-antigen tolerance is the proximate autoimmune abnormality.

Slide 13 · Familial and twin observations support heritability

Epidemiology points to substantial inherited susceptibility.

Monozygotic twins have greater disease concordance than dizygotic twins.

This contrast implicates genetic variation without proving genetic determinism.

Genetic studies subsequently identified multiple susceptibility loci.

Interpretive point

Genetic susceptibility changes probability; It does not make T1D inevitable.

Slide 14 · Twin discordance demonstrates incomplete penetrance

Concordance in monozygotic twins is only about 50% in the cited textbook.

Genes matter

Greater concordance

In identical twins

Genes are insufficient

Roughly half of identical

Twin pairs remain discordant

Genetically identical twins can have different disease outcomes.

Shared genetic predisposition is therefore insufficient to explain every case.

Nongenetic influences or stochastic events must contribute.

Slide 15 · T1D susceptibility is polygenic

Multiple loci participate in risk, with unequal contributions.

HLA region

The major histocompatibility complex is the strongest established region.

INS locus

Additional non-HLA variants point toward antigen expression and immune regulation.

Immune-regulatory loci

Risk-associated variants are not interchangeable with deterministic mutations.

Slide 16 · GWAS identifies risk loci, not a complete pathway

Genome-wide association studies support a multi-locus susceptibility model.

Association maps regions of the genome that track with disease risk.

A risk signal does not by itself prove which molecular mechanism is causal.

Functional interpretation requires immunologic and biological evidence.

Interpretive point

Association → candidate mechanism; Not automatically association → proven cause.

Slide 17 · HLA is the dominant susceptibility region

The HLA gene cluster is estimated to account for as much as 50% of genetic susceptibility in some analyses.

HLA

Major risk locus

Antigen presentation

HLA-associated risk is much stronger than that of most single non-HLA loci.

Its immune role links genotype to antigen recognition.

The precise means by which individual alleles confer risk remains unresolved.

Slide 18 · HLA class II molecules present antigenic peptides

Antigen display offers a biologic route from HLA variation to autoreactive T-cell responses.

HLA peptide-binding region

Peptide display

T-cell recognition

Autoimmune susceptibility

HLA molecules contain peptide-binding regions.

Risk polymorphisms cluster in or near these pockets.

Peptide presentation can affect the repertoire of T-cell responses.

Slide 19 · Peptide-binding pocket variants matter

The location of HLA polymorphisms supports—but does not prove—a mechanistic model.

Observed

Risk-associated variation

Near peptide-binding pockets

Interpretation

Potential alteration of

Relevant antigen display

Alternative HLA variants can display antigenic peptides differently.

This is consistent with a role in selection or activation of islet-reactive T cells.

The precise pathogenic explanation remains unknown.

Slide 20 · HLA-DR3 and HLA-DR4 are strongly enriched

Ancestry-specific association data for individuals of European descent.

90–95%

Affected with DR3 or DR4

≈40%

Unaffected with DR3 or DR4

90%–95% of affected individuals possess HLA-DR3 or HLA-DR4.

Approximately 40% of unaffected individuals possess one of these haplotypes.

Commonness in unaffected people shows that HLA status is not diagnostic.

Slide 21 · DR3/DR4 compound heterozygosity increases risk

A combined HLA genotype is overrepresented among individuals with T1D.

40–50%

Affected DR3/DR4 heterozygotes

≈5%

Unaffected DR3/DR4 heterozygotes

Approximately 40%–50% of patients are DR3/DR4 compound heterozygotes.

The textbook comparison is approximately 5% in unaffected subjects.

The association is substantial, but the genotype does not establish disease.

Slide 22 · DQ8 modifies inherited-risk combinations

Some high-risk combinations contain DR3 or DR4 together with DQ8.

DQ8

High-risk HLA

Configuration

The source highlights DR3/DR4-associated DQ8 configurations in sibling risk studies.

Combined haplotypes illustrate interactions within the HLA region.

Neither a single haplotype nor a combination predicts individual outcome with certainty.

Slide 23 · HLA association is not HLA causation

Strong epidemiologic association should not be overstated as a complete causal model.

Established

HLA strongly associates

With susceptibility

Unresolved

Exactly how particular alleles

Lead to disease

Many unaffected people carry HLA-DR3 or HLA-DR4.

Not all individuals with T1D share one risk genotype.

Allele-specific biologic mechanisms are still incompletely understood.

Slide 24 · Non-HLA loci broaden the susceptibility network

Other genetic risk signals converge on antigen availability and immune control.

Islet antigen context

INS-related variants may influence tolerance to insulin.

T-cell regulatory pathways

CTLA4 and PTPN22 variants implicate lymphocyte regulation.

Monogenic immune defects

Rare STAT3 or AIRE defects further support a tolerance-centered disease model.

Slide 25 · INS promoter tandem repeats are associated with T1D

A variable-number tandem-repeat (VNTR) region in the insulin gene promoter is a non-HLA susceptibility locus.

INS

Promoter VNTR

Candidate tolerance link

The association was the first recognized non-MHC genetic link described in the source.

The precise causal mechanism is not established.

Altered insulin expression within thymic antigen-presenting cells is one possibility.

Slide 26 · Thymic insulin expression is a tolerance hypothesis

Insulin expression in the thymus may help eliminate insulin-reactive developing T cells.

INS regulatory variation

Possible thymic expression change

Altered negative selection

Insulin-reactive T-cell escape

Developing T cells undergo negative selection against recognized self antigens.

INS promoter variation may alter thymic antigen display.

Reduced deletion of insulin-reactive clones is a proposed, not proven, explanation.

Slide 27 · Negative selection limits autoreactive T cells

Central tolerance is the first major immune checkpoint relevant to T1D.

Self-antigen display

T-cell recognition

Clonal deletion

Reduced autoreactivity

Self-reactive developing T cells can be deleted in the thymus.

Incomplete deletion leaves potentially harmful clones in the repertoire.

Genetic tolerance defects can make an islet-directed response more likely.

Slide 28 · CTLA4 susceptibility implicates immune restraint

CTLA4 is identified among non-HLA genes associated with T1D.

CTLA4

Immune checkpoint

T-cell restraint

CTLA4 participates in limiting T-cell activation.

Variation in this regulatory axis offers a plausible connection to loss of peripheral tolerance.

The gene association alone does not quantify an individual patient’s risk.

Slide 29 · PTPN22 links susceptibility to immune signaling

PTPN22 is another immune-regulatory susceptibility gene.

PTPN22

Immune signaling

Susceptibility locus

Its involvement supports a role for altered lymphocyte signaling thresholds.

This is compatible with aberrant survival or activation of autoreactive populations.

The supplied source does not establish a single universal causal route for its variants.

Slide 30 · STAT3 mutations underscore immune dysregulation

Patients with STAT3 mutations, T1D and other autoimmune disorders.

STAT3

Rare immune-regulatory

Mutation phenotype

STAT3-associated phenotypes show that defects in immune regulation can include β-cell autoimmunity.

These rare observations differ from common polygenic association signals.

They reinforce an immune-tolerance framework rather than a glucose-receptor defect.

Slide 31 · AIRE deficiency is a natural experiment in tolerance

Rare germline AIRE defects, associated with APS-1, carry marked susceptibility to T1D.

AIRE

Central tolerance

APS-1 association

AIRE is involved in central immune tolerance.

Its disruption supports the pathogenic importance of impaired selection against self antigens.

This rare syndrome is not the usual inheritance pattern for T1D.

Slide 32 · Distinct genetic loci converge on one vulnerability

The genetic landscape points repeatedly to breakdowns in antigen recognition and self-tolerance.

Antigen display

Central selection

Peripheral regulation

Islet-reactive T-cell risk

HLA influences which peptides are presented.

INS variants may affect availability of insulin antigen during selection.

Immune regulators affect survival, activation or restraint of T cells.

Slide 33 · Heritability cannot explain all disease risk

Genetic predisposition interacts with incompletely understood environmental influences.

Monozygotic twin discordance argues against a purely inherited model.

Exposure histories and immune responses may differ between genetically similar people.

The source does not identify a single established environmental trigger.

Interpretive point

Do not mistake a suspected trigger for a proven cause.

Slide 34 · The environmental contribution remains unresolved

Robbins explicitly describes the identity of relevant environmental influences as uncertain.

Supported

Nongenetic factors contribute

To overall susceptibility

Not established

One definitive exposure

Or necessary infectious cause

Environmental involvement is strongly suggested by incomplete twin concordance.

Candidate exposures have been studied, particularly antecedent infections.

No specific infection-to-T1D causal pathway is established in the supplied text.

Slide 35 · Viral infection is a proposed initiating factor

One hypothesis links a prior infection to subsequent islet-directed immune activity.

Possible infection

Immune activation

Possible cross-reaction

Islet injury hypothesis

A temporal association with infection does not prove causation.

Neither one virus nor one viral mechanism is established as the explanation.

The hypothesis must be framed as a candidate model.

Slide 36 · Molecular mimicry describes cross-reactivity

An antimicrobial immune response might recognize antigenic features shared by an islet protein.

Microbial epitope

Shared features with self

Cross-reactive response

Potential islet injury

A microbial epitope may resemble part of a self antigen.

Cross-reactive lymphocytes could then recognize β-cell targets.

This proposed mechanism has not been established as the universal cause of T1D.

Slide 37 · Biologic plausibility is not etiologic proof

Mechanism diagrams must separate what is demonstrated from what remains hypothetical.

Known

Disease involves autoimmune

β-cell destruction

Hypothesized

Antecedent virus triggers

Islet-specific autoimmunity

Molecular mimicry can be articulated as an immunologic mechanism.

For T1D, the source does not verify which virus or specific mimicry pathway initiates disease.

A correct teaching diagram should visibly mark the infection-related arrows as proposed.

Slide 38 · Some infections may instead be protective

The direction of infection-related effects may not be uniform.

Potentially harmful

Initiation or amplification

Of self-reactivity

Potentially protective

Modification of immune

Development or regulation

Certain infections have been proposed to protect against T1D.

That possibility opposes a simplistic “all infections cause T1D” model.

The underlying exposures and mechanisms are not resolved in the supplied text.

Slide 39 · Environment and genotype should be integrated

Environmental hypotheses operate in a genetically susceptible immune system.

Inherited context

A risk allele may influence which antigens can be presented.

Possible exposure

Environmental signals may alter immune activation or exposure to self antigens.

Immune outcome

Loss of tolerance is necessary to explain the autoimmune phenotype.

Slide 40 · Loss of self-tolerance is the fundamental defect

T1D autoimmunity begins when islet-reactive T cells are not adequately controlled.

Tolerance defect

Survival of autoreactive T cells

Islet antigen response

β-cell injury

Clonal deletion in the thymus may be defective.

Regulatory T-cell function may be insufficient.

Effector T cells may become less sensitive to regulation.

Slide 41 · Central tolerance failure permits clone survival

A thymic selection defect can leave self-reactive T cells available for later activation.

Effective selection

Self-reactive clone

Deleted

Defective selection

Self-reactive clone

Can persist

Effective central tolerance removes many dangerous self-reactive clones.

Defective deletion allows some cells to leave the thymus.

This is a proposed contributing defect rather than the sole proven route in every patient.

Slide 42 · Regulatory T-cell dysfunction weakens peripheral control

Regulatory T cells ordinarily restrain autoreactive immune activity.

Autoreactive cell survives

Insufficient Treg restraint

Sustained activation

Potential islet attack

Impaired regulation can permit stronger responses against islet antigens.

Tolerance failure need not originate exclusively in the thymus.

Peripheral dysregulation can combine with central selection defects.

Slide 43 · Effector cells may resist suppression

Even intact regulatory populations may fail if effector T cells respond poorly to restraint.

Regulatory-cell defect

Inadequate suppressive

Function

Effector-cell defect

Reduced sensitivity

To suppression

The source identifies abnormal effector-cell resistance as an additional possibility.

This mechanism differs from simply having too few regulatory T cells.

Both routes converge on inadequately controlled autoreactivity.

Slide 44 · Islet antigens may initiate local immune priming

Activated autoreactive T cells are thought to arise in peripancreatic lymph nodes.

Possible islet damage

Antigen release

Regional lymph node

T-cell activation

Antigens released from damaged islets may be delivered to regional nodes.

Islet-reactive T cells may be stimulated by those antigens.

This initial priming sequence is presented in the source as a proposed mechanism.

Slide 45 · Activated T cells can move from node to pancreas

The anatomic sequence connects peripheral activation with target-organ injury.

Peripancreatic node

Activated autoreactive T cells

Pancreatic islets

β-cell injury

Activated T cells travel toward the pancreas.

They encounter endogenous β-cell antigens in the islet environment.

Effector mechanisms then damage insulin-producing cells.

Slide 46 · CD8+ cytotoxic T cells kill β cells directly

CD8+ CTLs are among the implicated effector populations.

β-cell antigen recognition

CD8+ CTL engagement

Direct β-cell killing

Reduced β-cell mass

Target recognition enables contact-dependent cytotoxic injury.

This constitutes a direct cell-killing arm of autoimmune destruction.

Loss of β cells reduces the total insulin secretory reserve.

Slide 47 · Th1-type responses add cytokine-mediated injury

Th1 cells can secrete cytokines that injure the β-cell environment.

Th1 activation

IFN-γ / TNF release

Inflammatory injury

β-cell dysfunction / loss

The textbook specifically mentions interferon-γ and tumor necrosis factor.

Inflammatory cytokines contribute alongside direct cytotoxicity.

The relative weight of these mechanisms is not quantified in the source.

Slide 48 · Different T-cell populations cooperate in injury

T1D does not require a single effector-cell class to explain β-cell destruction.

CD8+ CTLs

Autoreactive CD8+ cells can mediate direct killing.

Th1 effectors

Th1-associated cytokines can promote inflammatory damage.

Regulatory failure

Regulatory failure enables these responses to persist.

Slide 49 · Insulin and GAD are recognized autoantigens

Insulin and glutamic acid decarboxylase among possible β-cell targets.

INS / GAD

Islet self-antigens

Targets of autoimmunity

Insulin is produced by the endocrine cell that is ultimately lost.

GAD is a β-cell enzyme and an autoantigenic target.

Other islet antigens can participate; The list is not exhaustive.

Slide 50 · Islet autoantibodies signal autoimmune activity

Autoantibodies against islet components occur in most patients, including before symptoms.

They provide evidence that an islet-specific autoimmune response exists.

Multiple autoantibodies are a defining element of stage 1 classification.

Their clinical value does not establish that they directly kill β cells.

Interpretive point

Biomarker of autoimmunity ≠ proven destructive effector.

Slide 51 · Antibody positivity and antibody pathogenicity differ

The source explicitly leaves the direct injurious role of autoantibodies unresolved.

Established

Autoantibodies appear

Before symptomatic T1D

Uncertain

Whether autoantibodies

Directly cause β-cell injury

Antibodies may participate in disease or may reflect an existing immune attack.

T cells are the principal effectors emphasized in the pathogenic model.

Avoid drawing an antibody-to-β-cell killing arrow as an established fact.

Slide 52 · Checkpoint blockade offers mechanistic support

Disrupting immune tolerance therapeutically can occasionally precipitate autoimmune diabetes.

Checkpoint blockade

Reduced immune restraint

Autoreactive activation

Occasional T1D

Cancer immune-checkpoint therapy alters normal immune restraint.

T1D sometimes develops after such treatment.

This observation reinforces the role of tolerance, without implying all T1D is therapy-induced.

Slide 53 · Immune injury is a multistep pathogenic circuit

No single risk allele or environmental proposal fully explains target-cell destruction.

Susceptibility / tolerance

Activation and migration

Cytotoxic / cytokine injury

Insulin reserve declines

Susceptible antigen presentation and failed self-tolerance allow autoreactivity.

Regional priming and pancreatic recruitment connect systemic immunity with islet injury.

Cytotoxic cells and inflammatory cytokines lower insulin reserve.

Slide 54 · The immune process predates overt diabetes

The clinical onset may be abrupt even though the autoimmune process is prolonged.

Preclinical β-cell autoimmunity can be identified by islet autoantibodies.

Functional reserve may decline before typical manifestations emerge.

Natural-history staging separates biological progression from symptom onset.

Interpretive point

Presymptomatic T1D is not the same state as absence of disease.

Slide 55 · Stage 1: Autoimmunity with normoglycemia

Stage 1 is presymptomatic, antibody-positive T1D with normal glucose regulation.

Stage 1

≥2 islet autoantibodies

Normoglycemia

No symptoms

Stage 2

Islet autoimmunity

Dysglycemia

No symptoms

Stage 3

Islet autoimmunity

Dysglycemia

Symptoms present

At least two islet autoantibodies are present.

Glycemic status remains normoglycemic.

Absence of symptoms does not mean absence of islet autoimmunity.

Slide 56 · Stage 2: Autoimmunity with dysglycemia

Stage 2 reflects progression of functional deficit before symptoms develop.

Stage 1

≥2 islet autoantibodies

Normoglycemia

No symptoms

Stage 2

Islet autoimmunity

Dysglycemia

No symptoms

Stage 3

Islet autoimmunity

Dysglycemia

Symptoms present

Islet autoimmunity persists.

Abnormal glucose handling indicates decreasing insulin capacity.

The person remains clinically presymptomatic.

Slide 57 · Stage 3: Symptomatic autoimmune diabetes

Stage 3 is marked by hyperglycemia and clinical manifestations.

Stage 1

≥2 islet autoantibodies

Normoglycemia

No symptoms

Stage 2

Islet autoimmunity

Dysglycemia

No symptoms

Stage 3

Islet autoimmunity

Dysglycemia

Symptoms present

Autoimmune β-cell injury has caused clinically significant insulin deficiency.

Polyuria, polydipsia and polyphagia may become apparent.

Ketoacidosis may occur when insulin deficiency is profound.

Slide 58 · The three stages differ in glycemia and symptoms

Stage definitions distinguish immune markers, glucose physiology and clinical state.

Dimension

Stage 1

Stage 2

Stage 3

Autoimmunity

≥2 islet autoantibodies

Present

Present

Glycemia

Normal

Dysglycemia

Dysglycemia

Symptoms

Absent

Absent

Present

All three stages belong to the continuum of autoimmune T1D.

Dysglycemia distinguishes stage 2 from stage 1.

Symptoms distinguish stage 3 from the two presymptomatic stages.

Slide 59 · Progression risk increases between early stages

Differing five-year probabilities of symptomatic progression.

<50%

Stage 1: Five-year progression

75%

Stage 2: Five-year progression

Stage 1: Fewer than 50% progress to symptoms within five years.

Stage 2: Approximately 75% progress within five years.

These values describe populations—not guaranteed individual outcomes.

Slide 60 · Major β-cell loss often precedes stage 3

Classic manifestations usually develop only after extensive target-cell destruction.

Symptoms typically appearing after destruction of more than 90% of β cells.

Loss of reserve can therefore remain hidden for a considerable time.

This figure is a teaching generalization, not a patient-specific measurement rule.

Interpretive point

Clinical symptoms occur late relative to initiation of immune injury.

Slide 61 · The staging sequence is clinically informative

Staging organizes a continuum without claiming that decline follows a uniform trajectory.

Stage 1

Antibodies + normal glucose

Stage 2

Antibodies + dysglycemia

Stage 3

Symptoms + dysglycemia

Stage 1 identifies presymptomatic autoimmunity.

Stage 2 adds loss of glycemic control without symptoms.

Stage 3 captures clinically manifest insulin deficiency.

Slide 62 · Symptoms reflect underlying insulin failure

Link the clinical triad to the metabolic state produced by β-cell loss.

Insulin deficiency

Hyperglycemia

Osmotic water loss

Polyuria / thirst

Hyperglycemia accompanies inadequate endogenous insulin action.

Osmotic consequences of hyperglycemia contribute to polyuria and polydipsia.

Polyphagia can occur despite excess circulating glucose.

Slide 63 · Insulin deficiency can progress to ketoacidosis

Profound insulin loss creates a risk of life-threatening metabolic decompensation.

Severe insulin deficiency

Loss of anti-lipolytic effect

Ketone-generating milieu

Ketoacidosis / coma risk

Reduced inhibition of adipose lipolysis increases fatty-acid mobilization.

Serious metabolic complications can include ketoacidosis and coma.

Most patients with T1D require insulin for survival.

Slide 64 · Case: Strong HLA risk does not equal diagnosis

An asymptomatic person has a DR3/DR4 genotype but no reported glucose abnormalities.

Reason through the mechanism

The genotype raises susceptibility relative to some other genotypes.

The presence of risk alleles alone does not demonstrate islet autoimmunity.

Additional clinical and immunologic evidence is needed to characterize disease status.

Question

Does HLA status alone establish T1D?

Interpretation

No. HLA is a susceptibility marker, not disease confirmation.

Slide 65 · Case: Multiple autoantibodies with normoglycemia

A screened relative has two islet autoantibodies, normal glycemia and no symptoms.

Reason through the mechanism

The combination corresponds to presymptomatic stage 1.

Normal glycemia does not negate established autoimmunity.

This state differs from simply having a high-risk HLA haplotype.

Question

Which natural-history stage fits?

Interpretation

Stage 1: Autoimmunity, normoglycemia, no symptoms.

Slide 66 · Case: Dysglycemia before symptoms

An autoantibody-positive individual develops impaired glucose tolerance but remains asymptomatic.

Reason through the mechanism

The metabolic abnormality indicates progression of functional β-cell loss.

The absence of symptoms still places the person in a presymptomatic state.

The natural-history classification is stage 2.

Question

What defines the transition from stage 1?

Interpretation

Dysglycemia, not the first appearance of polyuria or thirst.

Slide 67 · Case: Abrupt symptoms after silent decline

A previously well individual develops polyuria, polydipsia and symptomatic hyperglycemia.

Reason through the mechanism

The abrupt clinical presentation does not imply that immune injury began recently.

A prolonged loss of β-cell reserve may have preceded symptoms.

In an autoimmune T1D context, this presentation represents stage 3.

Question

How can onset be abrupt after a long disease course?

Interpretation

Symptoms emerge only after insulin reserve becomes insufficient.

Slide 68 · Evidence and hypothesis must be separated

Strong pathogenic conclusions and plausible but unresolved links should not be mixed.

Dimension

Established

Proposed

Unresolved

Pathogenic feature

T-cell–directed β-cell injury

Viral triggering via mimicry

Autoantibody effector role

Risk or response

Strong HLA association

Altered thymic insulin expression

Exact HLA-allele mechanism

Clearly established: Immune-mediated β-cell loss and HLA association.

Proposed: Specific infection-related molecular mimicry pathway.

Unresolved: Whether circulating autoantibodies directly injure β cells.

Slide 69 · Four common interpretation errors

Accurate pathogenesis requires avoiding shortcuts from risk markers to mechanisms.

Dimension

Incorrect shortcut

Why misleading

Better interpretation

“HLA means T1D”

Risk ≠ diagnosis

Assess immune and metabolic state

“Antibodies kill β cells”

Causality uncertain

Marker of islet autoimmunity

“Virus causes T1D”

Trigger not established

Candidate environmental factor

HLA risk is not sufficient to diagnose disease.

Autoantibodies can identify disease stage without proving direct injury.

An infectious hypothesis should not be narrated as a verified etiology.

Slide 70 · Integrated mechanism of type 1 diabetes

The teaching model combines risk architecture with a specifically autoimmune final pathway.

HLA + non-HLA risk

Tolerance failure

T-cell–mediated β-cell loss

Insulin deficiency / T1D

Genetic susceptibility and possible environment-related effects shape immune tolerance.

Autoreactive T-cell activation and migration enable β-cell injury.

Loss of endogenous insulin proceeds from silent stages to clinical disease.

Slide 71 · Core conclusions

The central explanation is progressive autoimmune β-cell injury arising in a susceptible host.

HLA is the largest recognized genetic contributor; Immune-regulator loci add risk.

Environmental triggers are suspected, but their identities and mechanisms remain uncertain.

T cells are central effectors; Islet autoantibodies are important indicators of autoimmunity.

Stage 1 → stage 2 → stage 3 links silent immune injury to symptomatic insulin deficiency.

Slide 72 · Principal reference and scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026).

The Endocrine System — Endocrine Pancreas: Pathogenesis of Type 1 Diabetes.

Adjacent teaching context: Genetic Susceptibility, Environmental Factors, and Mechanisms of β-Cell Destruction.

All mechanism illustrations in this lecture are original editable schematics rather than reproduced textbook figures.